Hrt Financial LP Atreca, Inc. Transaction History

Hrt Financial LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.13 - $0.38 $26,889 - $78,599	206,842 New	206,842 $27,000
Q1 2022 May 16, 2022	SELL	$1.61 - $5.2 $127,561 - $412,001	-79,231 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $129,692 - $284,238	45,189 Added 132.74%	79,231 $240,000
Q3 2021 Nov 15, 2021	SELL	$4.91 - $9.07 $344,696 - $636,741	-70,203 Reduced 67.34%	34,042 $212,000
Q2 2021 Aug 16, 2021	BUY	$7.82 - $13.8 $707,686 - $1.25 Million	90,497 Added 658.26%	104,245 $888,000
Q1 2021 May 17, 2021	BUY	$13.0 - $19.34 $178,724 - $265,886	13,748 New	13,748 $210,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.